Shmuel Cabilly

Develops and manufactures medical devices and monitoring tools

Designs and manufactures internal combustion engines

Develops pain monitoring devices

Develops antimicrobial coating technology for packaging, pads and devices

Develops point-of-care diagnostic devices that count and analyze blood cells

Develops AI to make the use and analysis of ultrasound images

Operates as a biopharmaceutical company that provides GI, infectious diseases, medical countermeasures and oncology services

Provides social health patient intelligence solutions

Provides medical devices and monitering tools

Develops medicines for the treatment of oncologic and dermatologic diseases

Develops AI-powered platform that provides medication management via advanced image recognition technology

Operates as aa clinical-stage oncology-focused biotechnology company

Develops anti-cancer immunotherapy treatment based on a natural plasma protein molecule

Provides technology solutions for mobile on-street, off-street and interactive parking

Develops innovative technology to treat obesity disease

Develops mitochondrial cell therapies for clinical-stage biotechnology company

Alonbio Ltd is an Israeli biotechnology company specializing in the discovery and development of targeted therapies for aggressive and difficult-to-treat advanced cancers. The company is based in Ness Ziona, Israel. The company focuses on cancers that overexpress proteins PRC1 and CDC25C, which are associated with poor prognosis in various solid and hematological malignancies. Key indications include triple-negative breast cancer, advanced lung cancer, and advanced colorectal cancer, all of which have high mortality rates and limited treatment options. Alonbio uses internal drug screening platforms and cancer biology research to translate scientific discoveries into treatments. The company's lead product, BKT300, is a selective inhibitor of PRC1 designed as a targeted therapy for advanced triple-negative breast cancer.